Literature DB >> 1444206

Polyamine deprivation enhances antitumoral efficacy of chemotherapy.

V Quemener1, J P Moulinoux, R Havouis, N Seiler.   

Abstract

We reported previously that polyamine deprivation by feeding a polyamine deficient diet combined with gastrointestinal tract decontamination and polyamine oxidase inhibition considerably enhanced the antitumoral effect of DFMO, a selective inhibitor of ornithine decarboxylase. The combination of polyamine deprivation and administration of well established cytotoxic drugs was expected to improve further the antitumoral effect of polyamine deprivation in Lewis lung carcinoma grafted in mice. Simultaneous treatment, i.e. administration of the cytotoxic drugs during the polyamine deprivation regimen, reduced tumor growth, but enhanced toxic effects. By alternating treatment and polyamine deprivation (1st day methotrexate (1.7 mg/kg), 2nd day cyclophosphamide (90 mg/kg), 3rd day vindesine (0.25 mg/kg), followed by five days of polyamine deprivation), tumor growth was reduced by 90% and an increase of 64% in the survival time of the animals was observed, demonstrating that a significant enhancement of the efficacy of chemotherapy was achieved without concomitant enhancement of toxic effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1444206

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

Review 1.  Current status of the polyamine research field.

Authors:  Anthony E Pegg; Robert A Casero
Journal:  Methods Mol Biol       Date:  2011

2.  Polyamine transport systems in mammalian cells and tissues.

Authors:  Takeshi Uemura; Eugene W Gerner
Journal:  Methods Mol Biol       Date:  2011

3.  Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract.

Authors:  Takeshi Uemura; David E Stringer; Karen A Blohm-Mangone; Eugene W Gerner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-06-03       Impact factor: 4.052

4.  In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.

Authors:  B Cipolla; Y Blanchard; L Chamaillard; V Quemener; F Guillé; R Havouis; J P Moulinoux
Journal:  Urol Res       Date:  1996

5.  Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis.

Authors:  Natalia A Ignatenko; David G Besselsen; Upal K Basu Roy; David E Stringer; Karen A Blohm-Mangone; Jose L Padilla-Torres; Jose M Guillen-R; Eugene W Gerner
Journal:  Nutr Cancer       Date:  2006       Impact factor: 2.900

Review 6.  Polyamines in brain tumor therapy.

Authors:  E S Redgate; S Boggs; A Grudziak; M Deutsch
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis.

Authors:  Upal K Basu Roy; Nathaniel S Rial; Karen L Kachel; Eugene W Gerner
Journal:  Mol Carcinog       Date:  2008-07       Impact factor: 4.784

Review 8.  The mechanisms by which polyamines accelerate tumor spread.

Authors:  Kuniyasu Soda
Journal:  J Exp Clin Cancer Res       Date:  2011-10-11

9.  Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.

Authors:  Laura D Gamble; Michael D Hogarty; Xueyuan Liu; David S Ziegler; Glenn Marshall; Murray D Norris; Michelle Haber
Journal:  Front Oncol       Date:  2012-11-16       Impact factor: 6.244

10.  Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.

Authors:  K P Raj; J A Zell; C L Rock; C E McLaren; C Zoumas-Morse; E W Gerner; F L Meyskens
Journal:  Br J Cancer       Date:  2013-01-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.